Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited, a clinical-stage biotech company, has shifted its principal business address to a new location in Camberwell, VIC and updated its contact number. The company, trading as Tryp on the ASX, specializes in developing intravenous psilocin therapies for untreated medical conditions and has recently reported successful Phase 2a trials for binge eating disorder, with ongoing trials for fibromyalgia and IBS. Tryp’s innovative IV-infused psilocin formulation aims to enhance patient outcomes by improving the administration and experience of psychedelic therapy.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
